Historical patterns indicate that abrupt fluctuations in the market can impact any firm, regardless of its seeming dominance.

Sales of Pfizer’s PFE COVID products, Comirnaty and Paxlovid, declined from their peak with the end of the pandemic. Their ...

Is Pfizer stock a buy at under 9x earnings? Yes. It is.

The stock has been fairly stable over the past year.

Pfizer India's shares surged after reporting strong Q3FY26 results, with net profit up 11% and revenue by 20%. The company ...

The pharmaceutical giant reaffirmed the modest 2026 outlook that rattled investors in December.

Evan Seigerman, head of healthcare research at BMO Capital Markets, joins 'Money Movers' to discuss Pfizer and Merck's latest ...

The stock gained 10.35% to hit intraday highs of ₹5,257, continuing its gaining streak from Monday, when it closed 3.79% ...

Analysts expect Pfizer’s revenue to decrease approximately 5% to around $16.95 billion, while adjusted earnings per share are projected to fall 9.5% to 57 cents compared to 63 cents in the same period ...

Pfizer posted adjusted earnings of 66 cents per share, beating the 57 cents forecast by analysts, News.Az reports, citing foreign ...

What does a successful retirement look like? If it means financial security through steady income sources, then you can get ...

Pfizer CEO Albert Bourla criticizes RFK's vaccine stance, warns US health research is losing ground to China, and urges stronger global competitiveness.